Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...
Experienced eye care professionals share their tips for enhanced clinical decision making and improved referrals within glaucoma care ...
Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the first patient in the international SAPPHIRE Trial has been treated with Avisi's ...
During his recent visit to Bangladesh, Assoc Prof Shamira Perera, Head of the Glaucoma Department at the Singapore National ...
The dots connect, the veil lifts and what was once confusing now feels undeniable Clarity arrives when you least expect it! On Nov. 29, Mercury will station direct, officially concluding a retrograde ...
Clarity arrives when you least expect it! On Nov. 29, Mercury will station direct, officially concluding a retrograde cycle that began in the truth-seeking sign of Sagittarius on Nov. 9. During this ...
PORTLAND, Ore. — I-5 will be closed south of downtown Portland for several hours starting late Monday night to install RealTime Variable Advisory Speed signs across all lanes of I-5, according to the ...
PORTLAND, Ore. (KPTV) - Interstate 5 will close overnight starting at 11 p.m. Monday and lasting until 5 a.m. Tuesday. The closure begins at I-405 and ends at Terwilliger Boulevard. Lane closures are ...
Men with benign prostatic hyperplasia (BPH) who took alpha-blockers to manage the condition were roughly 50% more likely to develop acute angle-closure glaucoma than were those who did not use the ...
Phase 3 AQUILA study showed DARZALEX FASPRO ® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...
"Until now, patients diagnosed with smoldering multiple myeloma only have the option to watch and wait for any active signs of progression to active disease," said Peter Voorhees, M.D., Atrium ...